These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12834696)

  • 1. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.
    Girmens JF; Erginay A; Massin P; Scigalla P; Gaudric A; Richard S
    Am J Ophthalmol; 2003 Jul; 136(1):194-6. PubMed ID: 12834696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.
    Aiello LP; George DJ; Cahill MT; Wong JS; Cavallerano J; Hannah AL; Kaelin WG
    Ophthalmology; 2002 Sep; 109(9):1745-51. PubMed ID: 12208726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease.
    Wong WT; Liang KJ; Hammel K; Coleman HR; Chew EY
    Ophthalmology; 2008 Nov; 115(11):1957-64. PubMed ID: 18789534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravitreal dexamethasone on macular edema in von Hippel-Lindau disease assessed using swept-source optical coherence tomography: a case report.
    Minnella AM; Pagliei V; Maceroni M; Federici M; Gambini G; Caporossi A
    J Med Case Rep; 2018 Sep; 12(1):248. PubMed ID: 30185211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verteporfin photodynamic therapy for retinal hemangioblastoma associated with Von Hippel-Lindau disease in a 9-year-old child.
    Lazzeri S; Figus M; Di Bartolo E; Rizzo S; Nardi M
    Clin Exp Ophthalmol; 2011 Mar; 39(2):179-81. PubMed ID: 21040313
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiangiogenic therapy for von Hippel-Lindau disease.
    Madhusudan S; Deplanque G; Braybrooke JP; Cattell E; Taylor M; Price P; Tsaloumas MD; Moore N; Huson SM; Adams C; Frith P; Scigalla P; Harris AL
    JAMA; 2004 Feb; 291(8):943-4. PubMed ID: 14982909
    [No Abstract]   [Full Text] [Related]  

  • 7. Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416.
    Schuch G; de Wit M; Höltje J; Laack E; Schilling G; Hossfeld DK; Fiedler W; Scigalla P; Jacobs MS
    J Clin Oncol; 2005 May; 23(15):3624-6. PubMed ID: 15908674
    [No Abstract]   [Full Text] [Related]  

  • 8. [Intravitreal anti-VEGF therapy for capillary hemangioblastomas in von Hippel-Lindau disease].
    Michels S; Messmer E; Sutter F; Kurz-Levin MM
    Klin Monbl Augenheilkd; 2008 Apr; 225(4):292-4. PubMed ID: 18401796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina.
    Dahr SS; Cusick M; Rodriguez-Coleman H; Srivastava SK; Thompson DJ; Linehan WM; Ferris FL; Chew EY
    Retina; 2007 Feb; 27(2):150-8. PubMed ID: 17290195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined therapy guided by multimodal imaging of fifteen retinal capillary hemangioblastomas in a monocular Von Hippel- Lindau syndrome case report.
    Guo J; Du L; Zhou P; Guo X; Dai F; Jin X
    BMC Ophthalmol; 2022 May; 22(1):205. PubMed ID: 35524216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Treatment Response of a Juxtapapillary Retinal Capillary Hemangioblastoma Due to von Hippel-Lindau Syndrome with Belzutifan in a Pediatric Patient.
    Mustafi D; Huang J; Ting MA; Waligorski N; Stacey AW; Huang LC
    Retina; 2024 May; 44(5):e31-e33. PubMed ID: 38100768
    [No Abstract]   [Full Text] [Related]  

  • 12. Photodynamic Therapy for Retinal Hemangioblastoma: Treatment Outcomes of 17 Consecutive Patients.
    Di Nicola M; Williams BK; Hua J; Bekerman VP; Mashayekhi A; Shields JA; Shields CL
    Ophthalmol Retina; 2022 Jan; 6(1):80-88. PubMed ID: 33892136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Retinal Changes Following Intravitreal Aflibercept in 2 Patients With Von Hippel-Lindau Disease-Related Retinal Capillary Hemangioblastoma.
    Konstantinou EK; Kodati S; Wiley HE; Keenan TDL; Cukras CA; Johnston RH; Thavikulwat AT
    JAMA Ophthalmol; 2022 Dec; 140(12):1243-1244. PubMed ID: 36301552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous angiogenesis inhibition in the treatment for von Hippel-Lindau-related hemangioblastomas of retina and spinal cord.
    Salim DK
    J Oncol Pharm Pract; 2019 Dec; 25(8):2049-2051. PubMed ID: 31694494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CLINICALLY INVISIBLE RETINAL HEMANGIOBLASTOMAS DETECTED BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY AND FLUORESCEIN ANGIOGRAPHY IN TWINS.
    Schoen MA; Shields CL; Say EAT; Douglass AM; Shields JA; Jampol LM
    Retin Cases Brief Rep; 2018 Winter; 12(1):12-16. PubMed ID: 27533642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy.
    Harris AL
    Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TWO CASES OF VON HIPPEL-LINDAU SYNDROME-ASSOCIATED RETINAL HEMANGIOBLASTOMA TREATED WITH BELZUTIFAN.
    Grimes JM; Gershkovich A; Bogomolny D; Marr BP
    Retin Cases Brief Rep; 2024 May; 18(3):319-322. PubMed ID: 36730578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of Optical Coherence Tomography Angiography Imaging in Diagnosis and Treatment of Hemangioblastomas in von Hippel-Lindau Disease.
    Lang SJ; Cakir B; Evers C; Ludwig F; Lange CA; Agostini HT
    Ophthalmic Surg Lasers Imaging Retina; 2016 Oct; 47(10):935-946. PubMed ID: 27759860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MANAGEMENT OF RETINAL HEMANGIOBLASTOMA IN VON HIPPEL-LINDAU DISEASE.
    Wiley HE; Krivosic V; Gaudric A; Gorin MB; Shields C; Shields J; Aronow ME; Chew EY
    Retina; 2019 Dec; 39(12):2254-2263. PubMed ID: 31259811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
    Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
    J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.